Both upatinib and fegotinib specifically target JAK1, among which upatinib is more effective than a TNF inhibitor in RA treatment, and fegotinib has the highest selectivity for JAK1 is convenient to take orally, and has a lower probability of adverse events compared with upatinib. The gene discussed is TNF; the disease is rheumatoid arthritis.